Vaxcyte, Inc. (PCVX) Guidance & Earnings Results
On 2025-08-06 Vaxcyte, Inc. reaffirmed guidance: "Phase 3 adult pivotal study to start Q4 2025 with topline data in 2026; infant Phase 2 modified study to proceed by end of Q3 2025 with topline data by end of H1…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PCVXVaxcyte, Inc.Follow PCVX — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 6 Aug 25 | Reaffirmed | Phase 3 adult pivotal study to start Q4 2025 with topline data in 2026; infant Phase 2 modified study to proceed by end of Q3 2025 with topline data by end of H1 2027. |
Vaxcyte, Inc. — questions
- What guidance did Vaxcyte, Inc. give?
- On 2025-08-06: "Phase 3 adult pivotal study to start Q4 2025 with topline data in 2026; infant Phase 2 modified study to proceed by end of Q3 2025 with topline data by end of H1 2027."
- When does Vaxcyte, Inc. report earnings?
- Vaxcyte, Inc.'s next earnings report is expected on 2026-11-09.
Every figure on this page comes from Vaxcyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.